Er du ikke helsepersonell? Besøk våre hjemmesider

Er du ikke helsepersonell?

Besøk gjerne våre sider for publikum.

Denne siden kan inneholde salgsfremmende materiell.

Handlekurv

User logged in

Rapporter bivirkning

Overlay Text

Kun for helsepersonell

Kan inneholde produktreklame

Din registrering er satt på vent

Din konto er aktivert, men fordi vårt system ikke umiddlebart kunne gjenkjenne deg som helsepersonell må det gjøres en manuell sjekk. Du vil motta en e-post med resulatet i løpet av få dager.

Fullført registrering – vent på godkjenning

Din konto er opprettet, men vi må likevel sjekke at du er registrert helsepersonell. Vi vil sende deg en e-post med resulatat i løpet av [5] dager.

I mellomtiden har du tilgang til alle tjenester på portalen.

Din registrering er satt på vent

Din konto er aktivert, men fordi vårt system ikke umiddlebart kunne gjenkjenne deg som helsepersonell må det gjøres en manuell sjekk. Du vil motta en e-post med resulatet i løpet av få dager.

Account activated – pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy access to all the latest news, events and resources on our website

X »

Anoro Ellipta 20 mcg

har blitt lagt til din handelkurv.

Se bestilling

Popup

Unit for Hours:H

Unit for Minutes: M

Filter redirection page URL: events-3-3.html

Filter Tags:Medical indications|Products|Therapy Area

Filter Tags values when filtered by all Tags:All Medical indications|All Products|All Therapy Area

OutofBox filter category name:Format

Filter Reset all button text:Reset All

Filter Apply button text:Apply

Events registration success message: Registration successfull

Events registration failure message: Registration failure

Events un-registration success message: Un-Registration successfull

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Tag Requirements value: all

Show More Naivagation Values: 10|25|50

Previous Text label: Previous

Next Text label: Next

Show Text label: Show:

Seats left Text: spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:$ciamTextareaNoCopyEmail

Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Pick section Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Severe Eosinophilic Asthma (SEA)

CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) – Dosing & administration

On this page

At home and in hospital dosing & administration

How to use Nucala

At home and in hospital dosing & administration

Nucala is a once-monthly biologic with a fixed-dose treatment for your patients with nasal polyps¹

Add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.¹

The recommended dose of mepolizumab is 100 mg administered SC once every 4 weeks.¹

Pre-filled pen

AT HOME
PRE-FILLED PEN

Pre-filled syringe

IN HOSPITAL
PRE-FILLED SYRINGE

Nucala as pre-filled pen or syringe may be self-administered by the patient or administered by a caregiver if their healthcare professional determines that it is appropriate, and the patient or caregiver are trained in injection techniques. For self-administration the recommended injection sites are the abdomen or thigh. A caregiver can also inject Nucala into the upper arm.

SELECTED SAFETY INFORMATION

Warnings/Precautions: Should not be used to treat acute asthma exacerbations. Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after starting treatment. Abrupt discontinuation of corticosteroids after initiation of mepolizumab treatment is not recommended.
Allergic reactions: Acute and delayed systemic reactions, including hypersensitivity reactions, have occurred following administration of mepolizumab. Patients should be instructed to seek medical attention immediately if allergic reactions occur. In the event of a hypersensitivity reaction, appropriate treatment as clinically indicated should be initiated.
Parasitic infections: Pre-existing helminth infections should be treated before starting therapy. If patients become infected whilst receiving treatment with mepolizumab and do not respond to anti-helminth treatment, temporary discontinuation of therapy should be considered.
Organ-threatening or life-threatening manifestations of EGPA and HES: Has not been studied
Adverse reactions: In clinical studies in patients with severe refractory eosinophilic asthma and EGPA, headache, injection site reactions and back pain were the most commonly reported adverse reactions during treatment. In patients with CRSwNP: Headache and back pain. In patients with HES: Headache, urinary tract infection, injection site reactions and pyrexia.